91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
91黑料's partnership with Advarra will integrate 91黑料’s global clinical trial solutions and services with Advarra’s site?CTMSs,?eISF, and?eSource?systems, which are already used by more than 50,000 investigators worldwide, including researchers at 90 of the top 125 academic medical centres.
-
91黑料 and Advarra partnership creates an integrated site-centric system that tackles operational bottlenecks and simplifies study execution, addressing sponsors most pressing challenges.
-
91黑料 and Advarra have partnered to create a connected network of clinical trial sites that integrates 91黑料’s global trial solutions with Advarra’s site technologies, aiming to streamline study operations, boost efficiency, and expand trial access.
-
91黑料 and Advarra have formed a partnership to create a connected, research ready site network that integrates 91黑料’s clinical trial services with Advarra’s site-facing technology to streamline study startup and trial execution. The collaboration aims to reduce administrative burden, enhance operational visibility, and broaden trial access by standardising workflows for both established and emerging research sites.
-
91黑料 plc and Advarra, a provider of connected, intelligence-powered research technology, have entered a partnership agreement to introduce a new ‘research-ready,’ connected site network model for clinical trials.
-
Every clinical trial has challenges, but trials researching SaMD use to treat mental health disorders have unique ethical, regulatory and technical ones. In this Applied Clinical Trials article 91黑料’s Devin Ridgley and JoAnne Bronikowski explore the implications of a vulnerable patient population and new technology.
-
As the cost of developing new therapies continues to rise, pharma executives must turn to technologies that drive better insights into de-risked investments and produce operational efficiencies. AI-powered digital measures are being developed and validated to better define disease, patients, and drug efficacy.
-
Read insights from Jennifer Eriksson, Divisional Principal, on the use of real-world evidence and real-world data to inform healthcare decision-making and provide patients with rapid access to innovative healthcare technology.
-
In this interview with Asia Business Outlook Magazine, Nagalakshmi Shetty, Vice President & India Country Head shares how changes in data management have changed the way clinical research is practiced and emphasises the role of interdisciplinary collaborations in progressing research.
-
This article by Gerard Quinn, Vice President of IT Innovation and Informatics, which appeared in PharmaTimes Magazine, delves into how AI is transforming clinical trials by improving efficiency, accelerating timelines, and enhancing decisions across the clinical development process.
